[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363800-105":59,"doc-detail-363800-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-mtfr1-as-a-novel-prognostic-biomarker-and-putative-oncogene-for-breast-cancer-a-multi-omics-analysis-and-in-vitro-experimental-validation","Identification of MTFR1 as a Novel Prognostic Biomarker and Putative Oncogene for Breast Cancer - A Multi-Omics Analysis and in Vitro Experimental Validation","","This open-access study investigates Mitochondrial Fission Regulator 1 (MTFR1) in breast cancer (BRCA) by integrating multi-omics data, spatial transcriptomics, and single-cell sequencing, followed by in vitro experiments. MTFR1 is markedly overexpressed in BRCA tissues, mainly localized to malignant cells, and tightly linked to cell-cycle progression. MTFR1 knockdown reduces proliferation, induces cell-cycle arrest, and shows high expression as an independent predictor of poor prognosis and chemotherapy resistance. Cross-cancer immunotherapy analyses indicate better anti-PD-1 response prediction in on-treatment settings. The work supports MTFR1 as a putative oncogene, prognostic biomarker, and therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-mtfr1-as-a-novel-prognostic-biomarker-and-putative-oncogene-for-breast-cancer-a-multi-omics-analysis-and-in-vitro-experimental-validation/363800/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-mtfr1-as-a-novel-prognostic-biomarker-and-putative-oncogene-for-breast-cancer-a-multi-omics-analysis-and-in-vitro-experimental-validation/363800.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study on MTFR1 in breast cancer?","Question",{"text":112,"@type":113},"To characterize MTFR1 in BRCA using multi-omics approaches and to validate its functional roles with in vitro experiments, including prognosis and treatment response implications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does MTFR1 affect breast cancer cells experimentally?",{"text":117,"@type":113},"MTFR1 knockdown suppresses cell proliferation and induces cell-cycle arrest, linking MTFR1 to cell-cycle progression.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical significance is associated with high MTFR1 expression?",{"text":121,"@type":113},"High MTFR1 expression serves as an independent predictor of poor prognosis and is associated with chemotherapy resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363800,1790197112,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","IET Systems Biology   \nORIGINAL RESEARCH  OPEN ACCESS   \nIdentification of MTFR1 as a Novel Prognostic Biomarker and Putative Oncogene for Breast Cancer: A Multi‐Omics Analysis and in Vitro Experimental Validation  \nYa Liu1 | Xiaofan Yuan2 | Hong Chen2   \n1Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China | 2Department of General Practice, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China  \nCorrespondence: Hong Chen ([Chenhong1153@163.com](Chenhong1153@163.com))  \nReceived: 21 February 2026 | Revised: 15 May 2026 | Accepted: 7 June 2026  \nKeywords: bioinformatics | cancer | gynaecology  \nABSTRACT  \nMitochondrial Fission Regulator 1 (MTFR1) plays a critical regulatory role in various malignancies; however, its specific function and clinical significance in breast cancer(BRCA) remain unexplored. This study systematically characterised MTFR1 by integrating multi‐omics data, spatial transcriptomics, and single‐cell sequencing, followed by in vitro experimental validation. MTFR1 was significantly overexpressed in BRCA tissues and predominantly localised to malignant cells. Functionally, MTFR1 was closely associated with cell cycle progression; in vitro knockdown significantly suppressed cell proliferation and induced cell cycle arrest. Clinically, high MTFR1 expression served as an independent predictor of poor prognosis and was linked to chemotherapy resistance. Cross‐cancer immunotherapy analyses revealed that MTFR1 exhibited improved predictive performance for anti‐PD‐1 response during the on‐treatment phase compared with pretreatment settings. This study elucidates the multidimensional role of MTFR1 as a putative oncogene in BRCA, highlighting it as a promising prognostic biomarker and therapeutic target.  \n1 | Introduction  \nBreast cancer (BRCA) remains one of the most prevalent and lethal malignancies affecting women worldwide [1] . Although advances in early detection and multimodal therapies have improved patient management, tumour heterogeneity, metastasis, and therapeutic resistance continue to pose major clinical challenges, often resulting in poor prognosis [2–4]. While precision medicine approaches based on molecular subtypes—such as LuminalA, Luminal B, HER2‐positive, and triple‐negative breast cancer—have enhanced clinical outcomes [5], the paucity of robust biomarkers and novel therapeutic targets limits the accurate prediction of disease progression and treatment response. Consequently, elucidating the molecular mechanisms driving BRCA progression is of critical clinical importance.  \nEmerging evidence underscores the pivotal role of mitochondrial dynamics—specifically the balance between fission and fusion—in tumour metabolic reprogramming, proliferation, and survival [6, 7]. Mitochondrial fission regulator 1 (MTFR1), a key nuclear‐encoded regulator of these dynamics, has been implicated in the pathology of various human diseases when dysregulated [8, 9] . In an oncological context, MTFR1 overexpression has been documented in multiple solid tumours, including colon cancer, lung adenocarcinoma, and tongue squamous cell carcinoma, where it promotes tumourigenesis by modulating the cell cycle, epithelial–mesenchymal transition (EMT), and chemotherapy resistance [10–12] . For instance, in lung adenocarcinoma, MTFR1 activates the AKT/mTOR pathway to enhance glycolysis and confer cisplatin resistance [12, 13], while  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s) . IET Systems Biology published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.  \nIET Systems Biology, 2026; 20:e70080 1 of 17  \n[https://doi.org/10.1049/syb2.70080](https://doi","cbCaifSIoKdyeYvJ","https://ap.wps.com/l/cbCaifSIoKdyeYvJ","pdf",9862621,17,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Datasets Acquisition","[{\"question\":\"What is the main objective of this study on MTFR1 in breast cancer?\",\"answer\":\"To characterize MTFR1 in BRCA using multi-omics approaches and to validate its functional roles with in vitro experiments, including prognosis and treatment response implications.\"},{\"question\":\"How does MTFR1 affect breast cancer cells experimentally?\",\"answer\":\"MTFR1 knockdown suppresses cell proliferation and induces cell-cycle arrest, linking MTFR1 to cell-cycle progression.\"},{\"question\":\"What clinical significance is associated with high MTFR1 expression?\",\"answer\":\"High MTFR1 expression serves as an independent predictor of poor prognosis and is associated with chemotherapy resistance.\"}]","Identification of MTFR1 as a Novel Prognostic Biomarker and Putative Oncogene for Breast Cancer - A Multi-Omics Analysis and in Vitro Experimental Validation | PDF",1790153222,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bd959f0061bc5c9356c2209b7022e52.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cd3cd67550fce4cb83e443a644a4f70.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f5efd8187855a0e8078075373945d36.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f3e7aff419dccc1c465e6cebdd4fa6d.webp",980,1287]